ArticlePrecision radiation oncology2026
One-year follow-up after fractionated ultra-high-dose-rate FLASH radiotherapy in patient with extramammary Paget disease of the scrotum.
Article in Precision radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ultrahigh-dose-rate radiotherapy (FLASH-RT) has been shown to reduce radiation-induced normal tissue injury in preclinical studies. Here, we describe the first patient worldwide to receive fractionated FLASH-RT. Methods: An elderly male patient was diagnosed with extramammary Paget disease of the scrotum along with multiple lymph node and bone metastases. After 6 cycles of chemotherapy, the disease progressed in the scrotum. The scrotal lesions were evaluated for FLASH-RT. 9 MeV electron FLASH-RT was performed at a dose rate of 120 Gy/s. The field size was 5 cm × 5 cm, and the prescribed dose was 40 Gy in five fractions. Dosimetric verification was performed daily. Treatment response was evaluated at 3-month post FLASH-RT, and normal tissue toxicity was assessed from the beginning of FLASH-RT to 12-month post-irradiation. Results: A 1-year follow-up was achieved for scrotal lesions treated with electron FLASH-RT in patients with extramammary Paget disease. Electron FLASH-RT was safe, and treatment-related adverse events were mild. Transient skin toxicity occurred 2-5 weeks post FLASH-RT, and exudation and burning pain were significantly alleviated. A complete response was achieved 2-3 months post FLASH-RT, and the tumor lesions were covered by the normal epithelium of the scrotum. At the end of the one-year follow-up, the tumor lesions continued to respond, and one-year survival was achieved without additional injury to the irradiated areas after FLASH-RT. Conclusion: Fractionated electron FLASH-RT is feasible and safe for the treatment of extramammary Paget disease of the scrotum. Our findings support further exploration of electron FLASH-RT in patients with skin tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.